Patents by Inventor Kenneth J. Holroyd
Kenneth J. Holroyd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110224406Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: ApplicationFiled: April 1, 2010Publication date: September 15, 2011Inventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 7704710Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: May 7, 2008Date of Patent: April 27, 2010Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Publication number: 20090105453Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: ApplicationFiled: May 7, 2008Publication date: April 23, 2009Inventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Publication number: 20090068185Abstract: A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.Type: ApplicationFiled: March 9, 2007Publication date: March 12, 2009Inventors: Kenneth J. Holroyd, Roy C. Levitt, W. Lee Maloy, Jamila Louahed, Mike McLane, Nicholas C. Nicolaides, Yuhong Zhou, Charles Qu Dong
-
Patent number: 7384767Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: January 31, 2007Date of Patent: June 10, 2008Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 7211254Abstract: A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.Type: GrantFiled: February 6, 2004Date of Patent: May 1, 2007Assignee: Genaera CorporationInventors: Kenneth J. Holroyd, Roy C. Levitt, W. Lee Maloy, Jamila Louahed, Mike McLane, Nicholas C. Nicolaides, Yuhong Zhou, Qu Dong
-
Patent number: 7208292Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: March 9, 2006Date of Patent: April 24, 2007Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 7056698Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: December 17, 2002Date of Patent: June 6, 2006Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Publication number: 20040204578Abstract: A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.Type: ApplicationFiled: February 6, 2004Publication date: October 14, 2004Applicant: Magainin Pharmaceuticals Inc.Inventors: Kenneth J. Holroyd, Roy C. Levitt, W. Lee Maloy, Jamila Louahed, Mike McLane, Nicholas C. Nicolaides, Yuhong Zhou, Qu Dong
-
Patent number: 6716603Abstract: A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.Type: GrantFiled: October 16, 2002Date of Patent: April 6, 2004Assignee: Genaera CorporationInventors: Kenneth J. Holroyd, Roy C. Levitt, W. Lee Maloy, Jamila Louahed, Mike McLane, Nicholas C. Nicolaides, Yuhong Zhou, Qu Dong
-
Patent number: 6602850Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: GrantFiled: June 16, 2000Date of Patent: August 5, 2003Assignee: Genaera CorporationInventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Publication number: 20030143687Abstract: This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 173. The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and the use of such DNA molecules and expressed protein in the diagnosis and treatment of atopic asthma.Type: ApplicationFiled: December 17, 2002Publication date: July 31, 2003Applicant: Magainin Pharmaceuticals Inc.Inventors: Roy Clifford Levitt, Luigi Grasso, Nicholas C. Nicolaides, Kenneth J. Holroyd
-
Patent number: 6576434Abstract: A new gene in the calcium-activated chloride channel family has been discovered that is induced by L-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered.Type: GrantFiled: February 13, 2001Date of Patent: June 10, 2003Assignee: Genaera CorporationInventors: Kenneth J. Holroyd, Roy C. Levitt, W. Lee Maloy, Jamila Louahed, Mike McLane, Nicholas C. Nicolaides, Yuhong Zhou, Qu Dong
-
Publication number: 20030078409Abstract: A new gene in the calcium-activated chloride channel family has been discovered that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and cystic fibrosis. A method for the identification and use of small molecule inhibitors of this gene and its products to treat these disorders has also been discovered. The invention also includes a method for diagnosing susceptibility to, and assessing treatment of atopic allergy, asthma-related disorders by measuring the level of gene expression in biologic samples using antibody specific for this protein.Type: ApplicationFiled: October 16, 2002Publication date: April 24, 2003Applicant: Magainin Pharmaceuticals Inc.Inventors: Kenneth J. Holroyd, Roy C. Levitt, W. Lee Maloy, Jamila Louahed, Mike McLane, Nicholas C. Nicolaides, Yuhong Zhou, Qu Dong